Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renal cell carcinoma vaccine - FBM Pharma

Drug Profile

Renal cell carcinoma vaccine - FBM Pharma

Alternative Names: Renal cell cancer vaccine - LipoNova; Renal cell cancer vaccine - Vaccentis; Reniale

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Liponova AG
  • Developer FBM-PHARMA
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cell carcinoma

Most Recent Events

  • 28 Jan 2019 Renal cell carcinoma vaccine is not yet available for Renal cell carcinoma (Adjuvant therapy) in Netherlands (Intradermal)
  • 15 Jun 2015 Renal cell carcinoma vaccine is still in phase-III development in the EU
  • 08 Feb 2014 Registered for Renal cell carcinoma (adjuvant therapy) in Austria (Intradermal) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top